FDA approves Lilly’s eczema drug Ebglyss for moderate-to-severe disease

Eli Lilly’s drug lebrikizumab has been approved for the treatment of eczema, or atopic dermatitis, a win for the company after the FDA rejected the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Meta Title: AstraZeneca Plc Patent: Improved AAV Vector Production with Specific Plasmid Sequence

Share this article According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca‘s grant share as

March 12, 2024

New comprehensive report on pediatric long COVID symptoms published

Up to 5.8 million children and youth in the U.S. have experienced symptoms of COVID-19 that persisted long after initial infection.

February 12, 2024

Researchers publish early results with new interleukin-targeting antibody – Pharmaceutical Technology

The antibody, which has been called Ab-IPL-IL-17, targets a sequence in both IL-17A and IL-17F. It has demonstrated positive results for rheumatoid arthritis treatment in

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.